Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization.
At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization.
The study will end for all other participants at 18 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 8 to <13 years.
VA, measured in each eye without cycloplegia in current refractive correction (if applicable) using the E-ETDRS VA protocol on a study-approved device displaying single surrounded optotypes, as follows:
Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated).
Criteria for strabismic amblyopia: At least one of the following must be met:
Criteria for anisometropia: At least one of the following criteria must be met:
Criteria for combined-mechanism: Both of the following criteria must be met:
No more than 2 weeks (cumulative) of prior dichoptic treatment
No treatment with cycloplegic eyedrops (e.g., atropine) in the past 2 weeks; other treatments allowed up to enrollment but then must be discontinued.
Refractive correction is required (single vision lenses or contact lenses) for any of the following refractive errors based on a cycloplegic refraction completed within the last 7 months:
NOTE: Children with cycloplegic refractive errors that do not fall within the requirements above for refractive correction may be given refractive correction at investigator discretion but must follow the study-specified prescribing guidelines, as detailed below.
NOTE: Monocular or binocular contact lens wear is allowed provided the contact lenses meet the refractive error correction requirements below. For each child, all testing must be performed using the same form of optical correction (i.e., no changing between contacts and spectacles).
Spectacles/contact lens correction prescribing instructions referenced to the cycloplegic refraction completed within the last 7 months:
Spectacles/contact lens correction (with or without other treatment such as patching) meeting the above criteria must be worn:
For at least 18 weeks OR until VA stability is documented (defined as <1-line change by the same testing method measured on 2 consecutive exams at least 9 weeks apart).
For determining VA stability (non-improvement):
Participant is willing to wear a headset.
Participant is willing to continue full-time spectacles/contact lens wear (if needed).
Interpupillary distance of 52mm to 72mm inclusive.
Investigator is willing to prescribe continued spectacles/contact lens correction (if needed) or either dichoptic device per protocol.
Participant is willing to accept assignment to either continued spectacles/ contact lens wear alone, dichoptic movies/shows (view 1 hour per day 6 days per week) OR dichoptic games (play approximately 25 minutes per day, 6 days per week) for 19 weeks.
Parent understands the protocol and is willing to accept randomization.
Parent has phone (or access to phone) and is willing to be contacted by JAEB Center staff.
Relocation outside of area of an active PEDIG site for this study within the next 36 weeks is not anticipated.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
252 participants in 3 patient groups
Loading...
Central trial contact
Brooke P Fimbel; Raymond T Kraker, MSPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal